A Maximum-Use Trial of Ruxolitinib Cream in Adolescents and Adults with Atopic Dermatitis

BACKGROUND: Ruxolitinib cream is a topical formulation of ruxolitinib, an inhibitor of Janus kinase 1 and Janus kinase 2. OBJECTIVE: We aimed to determine the safety, tolerability, and bioavailability of 1.5% ruxolitinib cream under maximum-use conditions in patients with atopic dermatitis. Efficacy...

Descripción completa

Detalles Bibliográficos
Autores principales: Bissonnette, Robert, Call, Robert S., Raoof, Tooraj, Zhu, Zhaoyin, Yeleswaram, Swamy, Gong, Xiaohua, Lee, Mark
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9142470/
https://www.ncbi.nlm.nih.gov/pubmed/35368221
http://dx.doi.org/10.1007/s40257-022-00690-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9142470/
https://www.ncbi.nlm.nih.gov/pubmed/35368221
http://dx.doi.org/10.1007/s40257-022-00690-3

Ejemplares similares